Galapagos
VC Fund
Mechelen-bovelingen, Belgium
Galapagos is a clinical-stage biotechnology company, specialized in the discovery and development of small molecule medicines with novel modes of action. Our ambition is to become a leading global biopharmaceutical company, focused on the discovery, development and commercialization of innovative medicines that will improve people's lives.
- Total investments:
- 5
- Last investment:
- Lead investor:
- 0%
Last updated:
For AI agents: llms.txt
Industries Galapagos invests in
Stages Galapagos invests in
Countries Galapagos invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
| See all 7 contacts → | |||
Round size
- Series A
- $52M–$125M
Investment Focus
Industry
- Biotechnology 4 (80%)
- Health Care 3 (60%)
- Life Science 3 (60%)
- Medical 2 (40%)
- Pharmaceutical 2 (40%)
Stage
- Seed 2 (40%)
- Series A 2 (40%)
- Series C 1 (20%)
Country
- United States 2 (40%)
- France 1 (20%)
- Belgium 1 (20%)
- The Netherlands 1 (20%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Andre Hoekema
Chief Business Officer
|
Chief Business Officer | Total investments: 0 | Find email | |
Kruti Popat
Director, Customer Insights & Engagement
|
Director, Customer Insights & Engagement | Total investments: 0 | Find email | |
Michele Manto
Chief Commercial Officer
|
Chief Commercial Officer | Total investments: 0 | Find email | |
Paul Passier
Director Clinical Pharmacology
|
Director Clinical Pharmacology | Total investments: 0 | Find email | |
Paul Stoffels
Chief Executive Officer
|
Chief Executive Officer | Total investments: 0 | Find email | |
| See all 7 team members → | ||||
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Coultreon Biopharma is developing best-in-class therapeutics that target clinically validated pathways in immunology and metabolic illnesses.Coultreon Biopharma employs extensive experience in disease biology, drug development, and translational science to identify the optimum treatment approach for addressing underlying illness biology withbest-in-class therapeutics. | $125M / Series A / Apr 28, 2026 | ||
| Third Arc Bio is a biotech company developing multifunctional antibodies for inflammatory and immunology diseases. Its drug development engine delivers superior biologics optimized to create T-cell engagement by leveraging two technologies that power a pipeline of high-value therapeutics – a solid tumor synergy platform and an I&I platformthat offers a novel approach to precision immune regulation at a tissue-specific level to achieve superior efficacy and safety. | $52M / Series A / Feb 04, 2026 | ||
| Terratis is a French company that uses the Sterile Insect Technique (SIT) to reduce the populations of tiger mosquitoes and agricultural pests. Their mission is to diminish harmful insect populations effectively on a large scale using a scientific, innovative, ecological, and efficient approach. | $1.6M / Seed / Mar 07, 2025 | ||
| Frontier Medicines’is a developer of a chemoproteomics platform intended to further accelerate the path to drug discovery. The company's platform integrates advanced computational approaches and machine learning to discover and pharmacologically target new binding pockets on proteins, making them accessible to small-molecule drug discovery anddevelopment, enabling patients to consume breakthrough medicines that redefine the course of debilitating diseases. | $80M / Series C / Feb 22, 2024 | ||
| Vitalnext brings together the worlds of Life Sciences and consumer products. We develop products with evidence-based health benefits for the ageing population. Healthy Ageing is an important topic in most societies throughout the world. The increasing life expectancy of most people creates a demand for products that keeps us in good health forprolonged periods of time. These products are commercialized via distribution- or licensing agreements with specialized business partners. Vitalnext’s most advanced product is an innovative medical nutrition that aims to not only improve body weight in malnourished people, but also improves the body composition in these patients by a preferential increase in muscle mass. | Seed / Jul 01, 2013 |
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does Galapagos invest in?
Galapagos invests primarily in Biotechnology, Health Care and Life Science startups, most often at Seed and Series A stage. Most of the 5 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What round sizes does Galapagos invest in?
Galapagos typically joins rounds of $52M–$125M at Series A. These are whole funding-round sizes, not Galapagos's own check, which is rarely disclosed: the 10th–90th percentile of the confirmed public funding rounds Galapagos took part in.
How do I contact Galapagos?
Public channels for Galapagos include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Galapagos?
The team at Galapagos includes Andre Hoekema (Chief Business Officer), Kruti Popat (Director, Customer Insights & Engagement) and Michele Manto (Chief Commercial Officer), among 7 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
